{"disease":{"id":"treatment-of-adult-patients-with-triglyceride-elevations-between-1-000-2-000-mg-dl-and-history-of-pancreatitis-or-recurrent-abdominal-pain-typical-of-pancreatitis","name":"Treatment of adult patients with triglyceride elevations between 1,000-2,000 mg/dL and history of pancreatitis or recurrent abdominal pain typical of pancreatitis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"lopid","indication_name":"Treatment of adult patients with triglyceride elevations between 1,000-2,000 mg/dL and history of pancreatitis or recurrent abdominal pain typical of pancreatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lopid","generic_name":"Gemfibrozil","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"PPAR-alpha (Peroxisome Proliferator-Activated Receptor Alpha)","drug_class":"Peroxisome Proliferator Receptor alpha Agonist [EPC]","quality_score":44,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"lopid","guideline_body":"FDA label","recommendation":"Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis.","line_of_therapy":"adj","evidence_grade":"B","guideline_year":null}],"source":"Drug Landscape verified database"}